Akebia Therapeutics Inc. (AKBA)
NASDAQ
Delayed Data
Oct 23, 2026, 01:30 PM
Day's Range
0.562052 wk Range
0.5420Overview - AKBA - Akebia Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
200.73M
P/E (Trailing)
-28.59
P/E (Forward)
-1.57
Price / Sales (TTM)
0.71
Price / Book
6.16
EV / EBITDA
-46.72
Profitability
Gross Margin
78.78%
Profit Margin
-13.54%
Operating Margin
-5.45%
Return on Assets
-1.05%
Return on Equity
-109.38%
Ownership
Shares Outstanding
271.74M
Float
272.25M
Short % of Shares Outstanding
8.22%
Held by Insiders
1.98%
Held by Institutions
40.72%
Price stats
Beta
0.18
50-Day Avg
0.8637
200-Day Avg
1.17
Analyst Consensus
6 analysts
Average price target
$ 3.80Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AKBA - Akebia Therapeutics Inc.
Peers - AKBA - Akebia Therapeutics Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- AKBANASDAQAkebia Therapeutics Inc.157.11MMarket Cap-459.08%52-week change-28.60P/E (Trailing)-13.54%Profit Margin
- NBIXNASDAQNeurocrine Biosciences, Inc.13.92BMarket Cap-4.14%52-week change19.90P/E (Trailing)20.91%Profit Margin
- ALKSNASDAQAlkermes plc6.91BMarket Cap+24.84%52-week change108.47P/E (Trailing)3.96%Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals, Inc.6.74BMarket Cap+47.11%52-week change39.14P/E (Trailing)5.04%Profit Margin
- LNTHNASDAQLantheus Holdings Inc.6.52BMarket Cap+42.25%52-week change24.14P/E (Trailing)17.69%Profit Margin
- KNSANASDAQKiniksa Pharmaceuticals Ltd6.21BMarket Cap+49.26%52-week change81.61P/E (Trailing)9.59%Profit Margin
- RGCNASDAQRegencell Bioscience Holdings Limited5.18BMarket Cap-50.72%52-week change-1433.33P/E (Trailing)0.00%Profit Margin
Profile Summary - AKBA - Akebia Therapeutics Inc.
About
Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with kidney disease. Its current product portfolio centers on treatments for chronic kidney disease-related complications, including anemia management and phosphorus control, supported by a…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
